Результаты поиска

The contribution of some environmental factors to the development of cow's milk and gluten intolerance in children.

The analysis performed by the authors includes correlation between certain environmental factors i.e. the kind of food (natural, mixed, artificial), the role of infection and therapy applied (including antibiotic therapy), living conditions (residence place, the age of parents, number of siblings) and the body birth weight and the established food intolerance in children. The patients were hospitalized at the Clinic of Infectious Diseases of Children during 1978-1982. There were 45 children aged from 5 months to 5 years with gluten intolerance and 50 children aged from 2 months to 5 years with

The contribution of some constitutional factors to the development of cow's milk and gluten intolerance in children.

The role of some constitutional factors in the development of cow's milk and gluten intolerance among hospitalized children was the subject of analysis made by the authors. The patients were hospitalized at the Clinic of Infectious Diseases of Children during 1973-1982. The age of 45 children varied from 5 months to 5 years (gluten intolerance group) and of 50 children it amounted to from 2 months to 5 years (cow's milk intolerance group). In 34% of the family members of the children with milk intolerance and in 4.4% of the family members of the children with gluten intolerance the symptoms of

The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy.

Antibody-Drug Conjugates (ADCs) have achieved significant success in cancer therapy by combining the targeting specificity of monoclonal antibodies with cytotoxic payloads. However, the concomitant issue of drug resistance has become increasingly prominent, with primary mechanisms including alterations in target antigen expression, impaired drug transport, and inhibition of cell death pathways. ADCs have also shown emerging therapeutic potential in the treatment of autoimmune diseases; for instance, ABBV-3373 has achieved initial success in this area, yet it also faces unique challenges such a

Совпадение в полном тексте источника
… Only through multi-center, longitudinal, large-sample clinical trials, as well as collaborative iteration between industry and academia, can these conceptual strategies be truly transformed into replicable, affordable, and durably effective therapeutic regimens. … Driven by multi-center evidence-based research and industry-academia collaboration, ADCs are poised to further enhance their safety and efficacy, becoming a solid pillar in the field of precision therapy for cancer and autoimmune diseases, and offering new hope and tangible improvements in survival and …

The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review.

ObjectiveTo ascertain trends in ototoxicity observed with monoclonal antibodies (mABs) and understand the impact they may have on hearing function.Data sourcesPubMed, Embase, Scopus.Review methodsA systematic review was performed following PRISMA guidelines. Data were reviewed for demographics, utilized mABs with respective indication and dosing, audiometric outcomes, and treatment for otologic effects.ResultsOf 757 studies reviewed, a total of 44 were included, encompassing 18,046 patients treated with mABs. Mean age of the sample was 57.8 years old. The search yielded 18 agents of ototoxicit

Совпадение в полном тексте источника
… Collaboration between otolaryngologists and audiologists should be encouraged in the management of these emerging symptoms, and as a field, it is critical to continue encouragement of formal, robust analysis of these ototoxic events in both industry and academia to help guide clinical assessment. …

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.

ObjectivesMolecular biomarker tests can inform the clinical management of genomic heterogeneous hematological malignancies, yet their availability in routine care largely depends on the supporting health economic evidence. This study aims to systematically review the economic evidence for recent molecular biomarker tests in hematological malignancies.MethodsWe conducted a systematic search in five electronic databases for studies published between January 2010 and October 2020. Publications were independently screened by two reviewers. Clinical study characteristics, economic methodology, and

Совпадение в полном тексте источника
… Majority of studies were published in a clinical journal ( n = 11; 79%) 24 , 25 , 27 , 28 , 29 , 30 , 32 , 33 , 34 , 35 , 36 rather than an economic or HTA journal ( n = 3; 21%). 26 , 31 , 37 More studies declared non‐industry (i.e., government, non‐government, and academia) funding ( n = 8; 57%) 24 …

Mass spectrometry-based metabolomics in health and medical science: a systematic review.

Metabolomics is the study of the investigation of small molecules derived from cellular and organism metabolism, which reflects the outcomes of the complex network of biochemical reactions in living systems. As the most recent member of the omics family, there has been notable progress in metabolomics in the last decade, mainly driven by the improvement in mass spectrometry (MS). MS-based metabolomic strategies in modern health and medical science studies provide innovative tools for novel diagnostic and prognostic approaches, as well as an augmented role in drug development, nutrition science

Совпадение в полном тексте источника
… Toxicity and adverse reactions of TCM have become a research hotspot in academia. …

Унификация одиссеи: искусственный интеллект для диагностирования и лечения редких заболеваний.

Подытожить текущие проблемы в диагностике и лечении редких заболеваний (РД), осветить последние достижения в области искусственного интеллекта (АИ) для РД и предложить модель будущего состояния лечения пациентов РД. Многодисциплинарный экспертный обзор с кратким изложением современных практических задач и мер по ограничению ставок в области РД-клиентов с учетом ключевых клинических и исследовательских соображений в отношении нормативных и экономических ограничений. 10,000 известные РД оказывают коллективное воздействие 1 В 10 Американцы, в целом 30 million Люди. Ежегодно на РД приходится свыше

Совпадение в полном тексте источника
… Diverse AI algorithms are being applied for RD diagnosis by government, academia, industry, and foundations, unfortunately without a coherent focus or direction. …

CAR-HEMATOTOX score as a predictor of hematotoxicity, infection, and survival after CAR T-cell therapy in hematologic malignancies: a systematic review and meta-analysis

BACKGROUND: Immune effector cell-associated hematotoxicity (ICAHT) is a common and clinically important toxicity after chimeric antigen receptor (CAR) T-cell therapy. The CAR-HEMATOTOX score, also reported as CAR-HT, is a baseline risk score proposed to identify patients at higher risk of hematotoxicity and related adverse outcomes. METHODS: We conducted a systematic search of PubMed, the Web of Science, and the Cochrane Library on June 19, 2026. Included studies compared high- and low-risk groups defined by the CAR-HEMATOTOX score after CAR T-cell therapy for hematologic malignancies and rep

Совпадение в полном тексте источника
… This study was supported by the Beijing University of Chinese Medicine Industry-Academia Collaboration Fund Project (Grant No. BUCM-2025-JS-FW-159). …

Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024.

BackgroundAdvanced therapy medicinal products (ATMPs) often require long-term monitoring to assess both safety and efficacy post-authorisation due to uncertainties identified during the approval process. This study aims to characterise the use of real-world data (RWD) in post-authorisation measures (PAMs) for ATMPs approved in the European Union.MethodsA systematic extraction of all PAMs from publicly available European Medicines Agency (EMA) regulatory documents for ATMPs approved between January 2013 and December 2024 was performed, followed by the identification of the presence and sources

Совпадение в полном тексте источника
… A more up-to-date analysis of RWD use in the post-authorisation setting would be highly relevant in evaluating the effectiveness of efforts by regulatory agencies, MAHs, academia, patient organisations and other stakeholders in leveraging such data for decision-making. …

Определение концепций физической активности, которые имеют клиническое значение для пациентов и лиц, обеспечивающих уход: систематический обзор качественных исследований.

Физическая активность (ПА) необходима для общего здоровья. Неоптимальная ПА связана с снижением качества жизни (QOL) и преждевременной смертью. При проведении клинических исследований и разработке терапевтических методов определение тех аспектов ПО, которые имеют значение для пациентов и лиц, обеспечивающих уход, имеет важнейшее значение для разработки специальных мероприятий, выявления индивидуальных контекстуальных факторов и повышения степени удовлетворенности пациентов и их участия в обеспечении их собственного благополучия. По мере быстрого развития цифровых технологий здравоохранения (ДТ

Совпадение в полном тексте источника
… Mobilise‐D research focused specifically on digital gait and mobility measures (DMO) development by combining a review with a Delphi‐based approach to achieve consensus on narrative definitions from research, academia, and industry [ 25 ]. …

Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma.

Adoptive cell therapy (ACT) has been studied in several human and canine cancers with some promising clinical outcomes but not in canine oral malignant melanoma (OMM). Our manuscript aimed to explore one kind of ACT, the ex vivo-expanded autologous immune cell infusion in canine OMM, as this tumor remains a treatment dilemma. The study recruited dogs with histopathological diagnoses of oral malignant melanoma, generated their peripheral blood mononuclear cells, expanded them into predominantly non-B non-T cells via stimulations of IL-15, IL-2, and IL-21, and then re-infused the cells into tumo

Совпадение в полном тексте источника
… All package plasmids (pLAS3w, pCMVΔR8.91, and pMD.G) were obtained from RNAi Core Laboratory in Academia Sinica, Taiwan. …

Antiseptic Functions of CGK012 against HMGB1-Mediated Septic Responses.

High mobility group box 1 (HMGB1), a protein with important functions, has been recognized as a potential therapeutic target for the treatment of sepsis. One possible mechanism for this is that inhibiting HMGB1 secretion can exert antiseptic effects, which can restore the integrity of the vascular barrier. (7S)-(+)-cyclopentyl carbamic acid 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester (CGK012) is a newly synthesized pyranocoumarin compound that could function as a novel small-molecule inhibitor of the Wnt/β-catenin signaling pathway. However, no studies have yet determi

Совпадение в полном тексте источника
… Collaboration between academia, industry, and regulatory agencies will also be essential in accelerating drug development timelines, enhancing research efficiency, and facilitating regulatory approval processes [ 28 ]. …

Novel Treatment Paradigms: Primary IgA Nephropathy.

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments. The therapeutic landscape in IgAN is rapidly evolving, driven in large part by the acceptance of the surrogate clinical trial end point of proteinuria reduction by regulatory authorities for the accelerated approval of new therapies. Two drugs, targeted release formulation (TRF)-budesonide (nefecon) and sparsentan, have recently been approved under this sch

Совпадение в полном тексте источника
… Each of the phase 3 trials in IgAN has generated a large biorepository of samples and the hope is that through collaboration between academia and industry, these samples can be studied to find the biomarkers we need to deliver truly personalized medicine to those living with IgAN. …

Precision Oncology-The Quest for Evidence.

The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopters continuing to carry a significant portion of the clinical and financial risk. Numerous innovative precision oncology trials have emerged globally to address the associated need for evidence of clinical utility. These studies seek to capitalize on the power of predictive biomarkers and/or treatment decision support analytics, to expeditiously and

Совпадение в полном тексте источника
… Introduction The advent of genomic technologies, such as next generation sequencing (NGS), has allowed for industry and academia to increasingly offer products and services that enable physicians to understand the therapeutic implications of patient data, based on the computational analysis of real-time …

Balancing Innovation and Access: Insights from AIM's Fair Pricing Model and Its Current and Future Applications.

OBJECTIVE: Access to affordable medicines is a cornerstone of equitable healthcare, yet escalating drug prices increasingly strain national healthcare systems. Cost-based pricing can be a useful complement to value-based pricing, provided that relevant variables are considered. METHODS: We applied the International Association of Mutual Benefit Societies (AIM) Fair Pricing Model to ten market-protected medicines authorized by the European Medicines Agency between 2015 and 2018, covering oncology, rare diseases, and chronic conditions. Analyses were conducted across six European countries-Belg

Совпадение в полном тексте источника
… In addition, partnering with pharmaceutical companies has limited academia’s influence to bring drugs to the market at affordable and sustainable prices, highlighting the need for better models of academic-led drug development paired with commercialization strategies [ 31 ]. …

Drug Repurposing in Veterinary Oncology: Myth or Reality?

Drug repurposing, that is, the identification of new therapeutic indications for existing medications, has been shown to be a cost-effective and time-efficient alternative to de novo drug development. This review provides a comprehensive overview of repurposed drugs in veterinary oncology, describing their mechanisms of action, current evidence of clinical benefit, and translational relevance. The therapeutic agents discussed include non-steroidal anti-inflammatory drugs (e.g., piroxicam), metabolic modulators (e.g., metformin), anti-parasitic drugs (e.g., fenbendazole), immunomodulators (e.g.

Совпадение в полном тексте источника
… The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs. Health Aff. 2015;34:286–293. doi: 10.1377/hlthaff.2014.1038. 7. Fogel D.B. …

Biotechnological Innovations from Ocean: Transpiring Role of Marine Drugs in Management of Chronic Disorders.

Marine drugs are abundant in number, comprise of a diverse range of structures with corresponding mechanisms of action, and hold promise for the discovery of new and better treatment approaches for the management of several chronic diseases. There are huge reserves of natural marine biological compounds, as 70 percent of the Earth is covered with oceans, indicating a diversity of chemical entities on the planet. The marine ecosystems are a rich source of bioactive products and have been explored for lead drug molecules that have proven to be novel therapeutic targets. Over the last 70 years, m

Совпадение в полном тексте источника
… Future Prospects of Marine Drugs and Drug Candidates Obtained from the Ocean For decades, a strong effort has been undertaken by the pharmaceutical industry and academia to derive therapeutically active marine drugs [ 78 ]. …

From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.

The insurgence of drug resistance in treating Multiple Myeloma (MM) still represents a major hamper in finding effective treatments, although over the past decades new classes of drugs, such as proteasome inhibitors and immunomodulatory drugs, have been discovered. Recently, our research team, within a Nature-Aided Drug Discovery project, isolated from Hibiscus Sabdariffa L. calyces the secondary metabolite called Hib-ester which possesses antiproliferative properties against human multiple myeloma RPMI 8226 cells, reduces migration and cell invasion and inhibits proteasome without neurotoxic

Совпадение в полном тексте источника
… Accordingly, chemotherapy remains the first-choice treatment, and researchers in both academia and pharma-companies are devoting intense efforts to leverage new technologies and scientific knowledge to successfully develop new effective therapies which will be able to change the patient’s quality and …

Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.

The complexity of cancer care requires integrated and continuous support to deliver appropriate care. An expert network with complementary expertise and the capability of multidisciplinary care is an integral part of contemporary oncology care. Appropriate infrastructure is necessary to empower this network to deliver personalized precision care to their patients. Providing decision support as cancer care becomes exponentially more complex with new diagnostic and therapeutic choices remains challenging. City of Hope has developed a Pyramidal Decision Support Framework to address these challeng

Совпадение в полном тексте источника
… The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community Am. Soc. Clin. Oncol. Educ. Book 2017 37 460 466 10.1200/edbk_174909 28561660 9. Seidman J. Masi D. Gomez-Rexrode A.E. …

Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management.

Nanotechnology is the science of nanoscale, which is the scale of nanometers or one billionth of a meter. Nanotechnology encompasses a broad range of technologies, materials, and manufacturing processes that are used to design and/or enhance many products, including medicinal products. This technology has achieved considerable progress in the oncology field in recent years. Most chemotherapeutic agents are not specific to the cancer cells they are intended to treat, and they can harm healthy cells, leading to numerous adverse effects. Due to this non-specific targeting, it is not feasible to a

Совпадение в полном тексте источника
… Ultimately, the integration of various enabling technologies and cross-collaboration with multidisciplinary theoretical and experimental scientists across academia and the pharmaceutical industry will accelerate these developments from the bench to the bedside and eventually to the market. …